Study Results from Eppley Institute for Research in Cancer in the Area of Cancer Published (The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer).

A recent study conducted by the Eppley Institute for Research in Cancer explores the immunomodulatory functions of the chemotherapy drug gemcitabine in cancer treatment. While immunotherapies have been successful in treating certain cancers, many types of cancer are still unresponsive to immune-based treatments and are primarily managed with chemotherapy drugs. The study highlights gemcitabine's potential as an immune-modifying agent and suggests that it could be used as a priming agent to enhance the efficacy of immunotherapy in traditionally insensitive cancers. The research aims to shed light on gemcitabine's influence on the immune system and its potential for combination therapies. [Extracted from the article]